Annita Kolnagou Selected Research

Deferoxamine (Desferal)

7/2020	Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications.
1/2018	Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
7/2017	Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
1/2011	Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
11/2010	Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
6/2010	Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
6/2010	Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
1/2008	Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
1/2008	Chelators controlling metal metabolism and toxicity pathways: applications in cancer prevention, diagnosis and treatment.
1/2008	Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Annita Kolnagou Research Topics

Disease

17	Iron Overload 07/2020 - 01/2003
10	Thalassemia 11/2019 - 01/2006
7	Iron Deficiencies 01/2021 - 01/2005
7	Neoplasms (Cancer) 07/2020 - 01/2008
6	beta-Thalassemia (Cooley's Anemia) 01/2013 - 06/2010
3	Friedreich Ataxia (Friedreich's Ataxia) 01/2018 - 01/2014
3	Infections 07/2017 - 01/2002
3	Cardiomyopathies (Cardiomyopathy) 01/2014 - 01/2006
2	Chronic Disease (Chronic Diseases) 12/2014 - 05/2013
2	Heart Failure 12/2014 - 01/2008
2	Hemochromatosis (Bronze Diabetes) 06/2010 - 01/2005
2	Heart Diseases (Heart Disease) 01/2006 - 11/2004
1	COVID-19 07/2021
1	Splenomegaly 07/2017
1	Transfusion-Related Acute Lung Injury 01/2017
1	Kidney Diseases (Kidney Disease) 01/2014
1	Communicable Diseases (Infectious Diseases) 05/2013
1	Anemia 05/2013
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2011
1	Mucormycosis 06/2010
1	Thrombosis (Thrombus) 01/2008
1	Cardiotoxicity 01/2008
1	Siderosis 01/2006
1	Neutropenia 01/2003
1	Arthralgia (Joint Pain) 01/2003
1	Agranulocytosis (Granulocytopenia) 01/2003
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2002

Drug/Important Bio-Agent (IBA)

23	IronIBA 01/2021 - 01/2002
20	DeferiproneIBA 01/2018 - 01/2002
15	Deferoxamine (Desferal)FDA LinkGeneric 07/2020 - 01/2003
7	Chelating AgentsIBA 01/2021 - 01/2006
6	Pharmaceutical PreparationsIBA 07/2021 - 01/2002
6	Ferritins (Ferritin)IBA 01/2018 - 01/2006
3	Free RadicalsIBA 07/2020 - 01/2008
3	Proteins (Proteins, Gene)FDA Link 12/2014 - 01/2008
2	Transferrin (beta 2 Transferrin)IBA 01/2018 - 01/2011
2	IonsIBA 01/2011 - 01/2008
2	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2011 - 01/2008
2	CopperIBA 01/2011 - 01/2008
2	MetalsIBA 01/2011 - 01/2008
2	ZincIBA 01/2008 - 01/2003
1	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2020
1	AntioxidantsIBA 07/2020
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 07/2020
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2017
1	AntibodiesIBA 01/2017
1	maltolIBA 11/2015
1	TropoloneIBA 11/2015
1	MimosineIBA 11/2015
1	FrataxinIBA 12/2014
1	Hemoglobins (Hemoglobin)IBA 05/2013
1	XenobioticsIBA 01/2013
1	SiderophoresIBA 06/2010
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2008
1	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2008
1	3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA 01/2008
1	Coordination ComplexesIBA 01/2008
1	Dexrazoxane (Zinecard)FDA LinkGeneric 01/2008
1	PlatinumIBA 01/2008
1	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2008
1	DNA (Deoxyribonucleic Acid)IBA 01/2008
1	Dietary IronIBA 01/2005

Therapy/Procedure

13	Therapeutics 07/2021 - 01/2002
5	Chelation Therapy (Therapy, Chelation) 01/2018 - 01/2006
1	Erythrocyte Transfusion 01/2017
1	Complementary Therapies (Alternative Medicine) 01/2014
1	Splenectomy 01/2013
1	Vascular Access Devices (Arterial Line) 01/2008